23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,
23andMe Cuts 40 Percent Of Its Workforce And Discontinues Therapeutics Division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.The latest restructuring efforts were announced by 23andMe on Monday.
23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a staggering 40 percent of
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe lays off 40% of its workforce, ends therapeutics division
Me is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe to lay off 40% of its workforce as stock price plummets
The genetic testing company 23andMe is cutting 40% of its workforce and ending its therapeutics program as its stock price continues to plummet. CBS News correspondent Carter Evans has more on what this means for its customers.
Hosted on MSN1d
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
Newser on MSN17h
Amid 'Substantial Doubt,' 23andMe Cuts 40% of Workers
The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year ...
Black Enterprise1d
23andMe Lays Off 40% Of Employees As Company Undergoes Restructuring
Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult ...
Yahoo Finance27d
Behind the scenes at 23andMe, questions about a star CEO
Anne Wojcicki, CEO of 23andMe, the struggling DNA testing company, doesn’t think this is the right time to examine her leadership style. “What will be most interesting is writing the story in ...